Welcome to our dedicated page for Cronos Group Common Share news (Ticker: CRON), a resource for investors and traders seeking the latest updates and insights on Cronos Group Common Share stock.
Cronos Group Inc. (CRON) is a globally diversified and vertically integrated cannabis company with a significant presence across four continents. Headquartered in Toronto, Canada, Cronos operates two wholly-owned Canadian licensed producers, Peace Naturals Project Inc. based in Ontario, and Original BC Ltd. located in British Columbia's Okanagan Valley. These operations are regulated under Health Canada's Access to Cannabis for Medical Purposes Regulations.
Internationally, Cronos has established production and distribution platforms in Israel and Australia, and through an exclusive distribution agreement, has access to over 12,000 pharmacies in Germany. The company focuses on building an iconic brand portfolio and developing disruptive intellectual property, aiming to be a leader in the global cannabis market.
Cronos's medicinal brand, Peace Naturals, and recreational brands, Cove and Spinach, cater to a wide range of consumers. The company exports medical cannabis primarily to Israel, and in the U.S., it holds an option to acquire 10.5% of U.S. multistate operator PharmaCann upon the easing of federal restrictions.
Recently, Cronos has expanded its footprint in Australia, partnering with Vitura to supply high-quality cannabis products. This milestone is significant as the Australian medical cannabis market has grown impressively, with approvals for new patients increasing each year. Additionally, Cronos's Spinach brand has become a top seller in Canada, particularly in the flower and edibles categories.
With a strong emphasis on R&D, Cronos invests in tissue culture and cannabis genetics breeding programs to ensure premium quality. This commitment has enabled the company to produce high-quality products that meet the growing demand in international markets, including the UK and Germany.
The company is also known for its commitment to responsible cannabis research, technology, and product development. With a focus on advancing consumer experiences, Cronos continues to innovate and expand its product offerings globally.
Cronos Group (NASDAQ: CRON) has issued a default status report following its application for a management cease trade order (MCTO) due to an inability to file its Quarterly Report on Form 10-Q for the period ending September 30, 2021, by the deadline. The MCTO, effective November 16, 2021, restricts trading by executives until necessary filings are made. Cronos anticipates filing by January 31, 2022, and reports no new material developments since the original announcement. The company is committed to compliance with alternative information guidelines while in default.
Cronos Group Inc. (NASDAQ: CRON) provides a default status report in compliance with NP 12-203 due to a management cease trade order (MCTO) stemming from its inability to file the Quarterly Report on Form 10-Q for Q3 2021 on time. The MCTO, issued on November 16, 2021, restricts trading by the CEO and CFO until the Required Filings are completed. The company aims to submit these filings by January 31, 2022, though this is not guaranteed. Cronos confirms no other significant changes since its initial announcement and will continue to comply with NP 12-203 guidelines.
Cronos Group Inc. (NASDAQ: CRON) has issued a default status report under NP 12-203 due to its inability to file the Quarterly Report on Form 10-Q for the period ending September 30, 2021, by the deadline. Following the announcement on November 9, 2021, a management cease trade order (MCTO) was issued on November 16, 2021, restricting trades by the CEO and CFO. The company is working to meet the filing deadline, now expected by January 31, 2022, and confirms that there have been no material changes since the original announcement.
NatuEra has launched the Holiday Chill Bundle, a collection of five CBD wellness products aimed at alleviating holiday stress. The bundle features tinctures, capsules, and gummies, all containing Lemon Balm and varying levels of CBD sourced from sustainably grown hemp in Colombia's Andes Mountains. Priced at $99.99, the bundle offers a 23% discount compared to individual purchases and includes free shipping. NatuEra's products are manufactured in GMP-certified facilities, ensuring high quality and compliance with U.S. standards.
Aurora Cannabis (ACB) and 22nd Century Group (XXII) announced a licensing agreement with Cronos Group (CRON) to advance cannabinoid biosynthesis research. This non-exclusive deal aims to enhance the production of rare cannabinoids such as CBG, CBC, and CBN efficiently and with high purity. According to CEO Miguel Martin, the collaboration is a significant step towards commercializing cannabinoid products, which could benefit health and wellness applications. Aurora and 22nd Century also plan to enforce their intellectual property rights against infringements.
Cronos Group (NASDAQ: CRON) reports on its management cease trade order (MCTO) issued on November 16, 2021, due to the inability to file the Quarterly Report on Form 10-Q for the period ending September 30, 2021. The MCTO restricts trading for executive officers until the required filings are made. The company confirms no material changes since the original announcement and is committed to fulfilling alternative information guidelines. Cronos continues to work toward completing the necessary filings and emphasizes forward-looking statements about potential risks and uncertainties.
Beatrice Society has announced the formation of its Board of Directors, appointing Gary Yeoman as Chairman. The board includes seasoned professionals Lorne Gertner and Krisztián Tóth. Yeoman, previously at Voxtur Analytics and Altus Group, aims to build on recent acquisitions in psychedelics and wellness. Gertner co-founded Cannasat Therapeutics and has notable ties to the cannabis industry, while Tóth specializes in corporate finance. The board's expertise is expected to strengthen Beatrice's position in the growing psychedelic therapy market.
Cronos Group (NASDAQ: CRON) issued a default status report after applying for a Management Cease Trade Order (MCTO) due to an inability to file its Quarterly Report on Form 10-Q for the period ending September 30, 2021. The MCTO restricts trading by the CEO and CFO until filings are complete, but not for other shareholders. The company received a notice from Nasdaq regarding non-compliance with listing requirements. No material changes have occurred since the original announcement, and management is actively working on the required filings.
Cronos Group has filed a Form 12b-25 with the SEC regarding its Quarterly Report on Form 10-Q for the period ending September 30, 2021. The delay is due to the Audit Committee needing more time to assess goodwill and indefinite-lived intangible assets for impairment, expecting a charge of at least $220 million. This charge won’t impact cash or revenues, but the Company anticipates filing the complete Form 10-Q within 60 days. Additionally, a management cease trade order has been applied for, restricting trading by certain executives until the filings are completed.
Cronos Group Inc. (NASDAQ: CRON) announced Dr. Todd Abraham's retirement as Chief Innovation Officer after 40 years, with Arye Weigensberg assuming the interim role. Weigensberg, previously General Manager at Cronos Research Labs, will lead R&D while the company searches for a permanent successor. Dr. Abraham's contributions included spearheading the partnership with Ginkgo Bioworks, which led to the launch of the Spinach FEELZ™ Chill Bliss gummy. Cronos aims to continue advancing cannabis innovations and enhancing consumer experience.
FAQ
What is the current stock price of Cronos Group Common Share (CRON)?
What is the market cap of Cronos Group Common Share (CRON)?
What does Cronos Group Inc. do?
Where is Cronos Group headquartered?
Which brands does Cronos Group own?
What are Cronos Group's international operations?
What recent achievement has Cronos made in Australia?
What is the significance of the Spinach brand for Cronos?
Does Cronos export medical cannabis to other countries?
What research and development efforts is Cronos involved in?
What is Cronos's goal in the cannabis market?
What option does Cronos hold in the United States?
